Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;222(7):e20242250.
doi: 10.1084/jem.20242250. Epub 2025 Apr 24.

Sympathetic axonogenesis promotes adenoid cystic carcinoma progression

Affiliations

Sympathetic axonogenesis promotes adenoid cystic carcinoma progression

Chun-Hao Chen et al. J Exp Med. .

Abstract

Nerves are integral to the adenoid cystic carcinoma (ACC) microenvironment. The strong association of ACC with perineural invasion (PNI) is considered a hallmark of this disease. In human salivary ACC, we identify intratumoral, small-caliber, disorganized sympathetic nerves not observed in other salivary neoplasms. Norepinephrine or sympathetic ganglia explants enhance ACC proliferation in vitro. Two novel orthotopic ACC patient-derived xenograft (PDX) models recapitulate ACC morphology and demonstrate sympathetic innervation. Pharmacologic or surgical blockade of sympathetic nerves decreases ACC PDX growth. Bulk RNA sequencing of salivary ACC reveals correlations between noradrenergic nerve development signatures and worse patient survival. Metastatic ACC foci exhibit lower nerve signature gene expression levels than primary ACC. Sympathetic innervation in ACC is distinct from PNI and reflects tumor axonogenesis driven by noradrenergic neural development programs. These programs support ACC progression, are associated with poor prognosis, and may be inhibited as a therapeutic strategy.

PubMed Disclaimer

Conflict of interest statement

Disclosures: A.L. Ho reported personal fees from Physician Education Resources and Takeda; grants from Daichi Sankyo; other from Lepu Biopharma and Hookipa; grants from Rgenta Therapeutics and Remix Therapeutics; personal fees from Nested Therapeutics, Exelixis, Eisai, Affyimmune, and Kura Oncology; grants from Merck; personal fees from ExpertConnect, Elevar Therapeutics, and Prelude Therapeutics; grants from Verastem, Bayer, Genentech, Kura Oncology, Eisai, and BMS; personal fees from Remix Therapeutics and Rgenta Therapeutics; grants from Astellas, Novartis, and AstraZeneca; and personal fees from Inhibrx outside the submitted work. In addition, A.L. Ho had a patent on lesional dosimetry methods for tailoring targeted radiotherapy in cancer, serial no. 63/193700, filed 5/27/2021, pending. No other disclosures were reported.

References

    1. Albo, D., Akay C.L., Marshall C.L., Wilks J.A., Verstovsek G., Liu H., Agarwal N., Berger D.H., and Ayala G.E.. 2011. Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes. Cancer. 117:4834–4845. 10.1002/cncr.26117 - DOI - PubMed
    1. Amit, M., Binenbaum Y., Trejo-Leider L., Sharma K., Ramer N., Ramer I., Agbetoba A., Miles B., Yang X., Lei D., et al. 2015. International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck. 37:1038–1045. 10.1002/hed.23710 - DOI - PubMed
    1. Amit, M., Takahashi H., Dragomir M.P., Lindemann A., Gleber-Netto F.O., Pickering C.R., Anfossi S., Osman A.A., Cai Y., Wang R., et al. 2020. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 578:449–454. 10.1038/s41586-020-1996-3 - DOI - PMC - PubMed
    1. Amit, M., Anastasaki C., Dantzer C., Demir I.E., Deneen B., Dixon K.O., Egeblad M., Gibson E.M., Hervey-Jumper S.L., Hondermarck H., et al. 2024. Next Directions in the Neuroscience of Cancers Arising outside the CNS. Cancer Discov. 14:669–673. 10.1158/2159-8290.CD-23-1495 - DOI - PubMed
    1. Ayala, G.E., Dai H., Powell M., Li R., Ding Y., Wheeler T.M., Shine D., Kadmon D., Thompson T., Miles B.J., et al. 2008. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin. Cancer Res. 14:7593–7603. 10.1158/1078-0432.CCR-08-1164 - DOI - PubMed

LinkOut - more resources